Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study
Scancell Holdings plc, a developer of immunotherapies, today (November 7) announced it has in-licensed the…
November 7, 2022 - 3 minutes
Scancell Holdings plc, a developer of immunotherapies, today (November 7) announced it has in-licensed the…
The first patient in an expansion phase of a trial looking at cancer drug Modi-1…
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer and infectious…
The major research funder CRUK and two of the biotech companies it works with have…
Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer…